Table 2.
Univariate analysis for time to recurrence
| Characteristics | Hazard ratio (95 % CI) | p-value |
|---|---|---|
| Location of primary tumor (rectum vs colon) | 0.956 (0.548–1.669) | 0.875 |
| Age (≥65 vs <65) | 0.856 (0.418–1.755) | 0.671 |
| Sex (female vs male) | 0.678 (0.399–1.150) | 0.150 |
| Neoadjuvant chemotherapy (Yes vs No) | 1.040 (0.563–1.923) | 0.899 |
| Tumor grade (moderate/poor vs well) | 1.201 (0.508–2.843) | 0.676 |
| T stage (T4 vs T1-3) | 1.041 (0.608–1.782) | 0.885 |
| N stage (N2 vs N0,1) | 1.197 (0.703–2.037) | 0.508 |
| Resection site | ||
| Liver | 1 | |
| Lung | 0.694 (0.311–1.550) | 0.373 |
| Others (ovary, uterus, bladder) | 0.670 (0.299–1.502) | 0.331 |
| Use of Cetuximab at 1st post-operative chemotherapy (Yes vs No) | 0.589 (0.143–2.425) | 0.463 |
| Use of Bevacizumab at 1st post-operative chemotherapy (Yes vs No) | 0.582 (0.231–1.469) | 0.252 |
| KRAS (mutation vs wild) | 1.245 (0.725–2.137) | 1.245 |
| KRAS subtype | ||
| Wild | 1 | |
| 12th | 1.127 (0.599–2.123) | 0.710 |
| 13th | 1.230 (0.561–2.697) | 0.605 |
| A.A Mutation type | ||
| Wild (n = 51) | 1 | |
| Guanine to thymidine (n = 5) | 0.737 (0.164–3.315) | 0.691 |
| Guanine to cytosine (n = 2) | 1.482 (0.766–2.864) | 0.242 |
| Guanine to adenine (n = 24) | 1.029 (0.553–1.931) | 0.928 |
Abbreviations: CI confidence interval, A.A amino acid, HR hazard ratio